306 related articles for article (PubMed ID: 31695514)
1. Clinical Utility Of Elagolix As An Oral Treatment For Women With Uterine Fibroids: A Short Report On The Emerging Efficacy Data.
Neri M; Melis GB; Giancane E; Vallerino V; Pilloni M; Piras B; Loddo A; Paoletti AM; Mais V
Int J Womens Health; 2019; 11():535-546. PubMed ID: 31695514
[TBL] [Abstract][Full Text] [Related]
2. Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids.
Al-Hendy A; Bradley L; Owens CD; Wang H; Barnhart KT; Feinberg E; Schlaff WD; Puscheck EE; Wang A; Gillispie V; Hurtado S; Muneyyirci-Delale O; Archer DF; Carr BR; Simon JA; Stewart EA
Am J Obstet Gynecol; 2021 Jan; 224(1):72.e1-72.e50. PubMed ID: 32702363
[TBL] [Abstract][Full Text] [Related]
3. Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids.
Schlaff WD; Ackerman RT; Al-Hendy A; Archer DF; Barnhart KT; Bradley LD; Carr BR; Feinberg EC; Hurtado SM; Kim J; Liu R; Mabey RG; Owens CD; Poindexter A; Puscheck EE; Rodriguez-Ginorio H; Simon JA; Soliman AM; Stewart EA; Watts NB; Muneyyirci-Delale O
N Engl J Med; 2020 Jan; 382(4):328-340. PubMed ID: 31971678
[TBL] [Abstract][Full Text] [Related]
4. Elagolix in the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
Ali M; A R S; Al Hendy A
Expert Rev Clin Pharmacol; 2021 Apr; 14(4):427-437. PubMed ID: 33682578
[TBL] [Abstract][Full Text] [Related]
5. The management of uterine leiomyomas.
Vilos GA; Allaire C; Laberge PY; Leyland N;
J Obstet Gynaecol Can; 2015 Feb; 37(2):157-178. PubMed ID: 25767949
[TBL] [Abstract][Full Text] [Related]
6. Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids.
Stewart EA; Archer DF; Owens CD; Barnhart KT; Bradley LD; Feinberg EC; Gillispie-Bell V; Imudia AN; Liu R; Kim JH; Al-Hendy A
J Womens Health (Larchmt); 2022 May; 31(5):698-705. PubMed ID: 34582715
[No Abstract] [Full Text] [Related]
7. Oriahnn: New Drug Approved for Treating Heavy Menstrual Bleeding in Women With Uterine Fibroids.
Lynch SE; Mayer DC
Ann Pharmacother; 2022 Jan; 56(1):93-101. PubMed ID: 33998300
[TBL] [Abstract][Full Text] [Related]
8. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study.
Archer DF; Stewart EA; Jain RI; Feldman RA; Lukes AS; North JD; Soliman AM; Gao J; Ng JW; Chwalisz K
Fertil Steril; 2017 Jul; 108(1):152-160.e4. PubMed ID: 28579415
[TBL] [Abstract][Full Text] [Related]
9. Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial.
Carr BR; Stewart EA; Archer DF; Al-Hendy A; Bradley L; Watts NB; Diamond MP; Gao J; Owens CD; Chwalisz K; Duan WR; Soliman AM; Dufek MB; Simon JA
Obstet Gynecol; 2018 Nov; 132(5):1252-1264. PubMed ID: 30303923
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis.
Muneyyirci-Delale O; Archer DF; Owens CD; Barnhart KT; Bradley LD; Feinberg E; Gillispie V; Hurtado S; Kim JH; Wang A; Wang H; Stewart EA
F S Rep; 2021 Sep; 2(3):338-346. PubMed ID: 34553161
[TBL] [Abstract][Full Text] [Related]
11. Current approaches to overcome the side effects of GnRH analogs in the treatment of patients with uterine fibroids.
Ali M; Raslan M; Ciebiera M; Zaręba K; Al-Hendy A
Expert Opin Drug Saf; 2022 Apr; 21(4):477-486. PubMed ID: 34612122
[TBL] [Abstract][Full Text] [Related]
12. Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas.
Simon JA; Al-Hendy A; Archer DF; Barnhart KT; Bradley LD; Carr BR; Dayspring T; Feinberg EC; Gillispie V; Hurtado S; Kim J; Liu R; Owens CD; Muneyyirci-Delale O; Wang A; Watts NB; Schlaff WD
Obstet Gynecol; 2020 Jun; 135(6):1313-1326. PubMed ID: 32459423
[TBL] [Abstract][Full Text] [Related]
13. Elagolix: First Global Approval.
Lamb YN
Drugs; 2018 Sep; 78(14):1501-1508. PubMed ID: 30194661
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics of Elagolix in Combination with Low-Dose Estradiol/Norethindrone Acetate in Women with Uterine Fibroids.
Beck D; Winzenborg I; Liu M; Degner J; Mostafa NM; Noertersheuser P; Shebley M
Clin Pharmacokinet; 2022 Apr; 61(4):577-587. PubMed ID: 34878624
[TBL] [Abstract][Full Text] [Related]
15. The modern management of uterine fibroids-related abnormal uterine bleeding.
Vannuccini S; Petraglia F; Carmona F; Calaf J; Chapron C
Fertil Steril; 2024 May; ():. PubMed ID: 38723935
[TBL] [Abstract][Full Text] [Related]
16. Oral Gonadotropin-Releasing Hormone Antagonists in the Treatment of Uterine Myomas: A Systematic Review and Network Meta-analysis of Efficacy Parameters and Adverse Effects.
Telek SB; Gurbuz Z; Kalafat E; Ata B
J Minim Invasive Gynecol; 2022 May; 29(5):613-625. PubMed ID: 34942350
[TBL] [Abstract][Full Text] [Related]
17. Highlights on Medical Treatment of Uterine Fibroids.
Angioni S; D'Alterio MN; Daniilidis A
Curr Pharm Des; 2021; 27(36):3821-3832. PubMed ID: 33388011
[TBL] [Abstract][Full Text] [Related]
18. The potential role of elagolix for treating uterine bleeding associated to uterine myomas.
Barra F; Vitale SG; Seca M; Scala C; Leone Roberti Maggiore U; Cianci A; Ferrero S
Expert Opin Pharmacother; 2020 Aug; 21(12):1419-1430. PubMed ID: 32401547
[TBL] [Abstract][Full Text] [Related]
19. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
Murji A; Whitaker L; Chow TL; Sobel ML
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
[TBL] [Abstract][Full Text] [Related]
20. Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis.
Arjona Ferreira JC; Migoya E
F S Rep; 2023 Jun; 4(2 Suppl):73-82. PubMed ID: 37223761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
